Global Phase 3 Trial of AMX0035 to Enroll 600 ALS Patients, Amylyx Says
A global Phase 3 trial of AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS) intends to enroll up to 600 patients, the therapy’s developer, Amylyx Pharmaceuticals, announced in a press release. Likely to begin in the coming months, the trial — to be called PHOENIX…